Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase I/II Trial to Evaluate the Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

NCT04179760 is registered in ClinicalTrials.gov with SCM Lifescience Co., LTD. as lead sponsor.

NCT NCT04179760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase I/II Trial to Evaluate the Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
SCM Lifescience Co., LTD.
Phase
Phase 1/2
Overall status
Completed
Start date
March 24, 2020
Completion date
October 26, 2022
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic